Sana Biotechnology Appoints Brian Piper as CFO

Piper brings over 25 years of biopharmaceutical financial and operational expertise to the company.

Published on Feb. 20, 2026

Got story updates? Submit your updates here. ›

Sana Biotechnology, Inc. has announced the appointment of Brian Piper as Executive Vice President and Chief Financial Officer. Piper previously served as CFO of Scorpion Therapeutics and its spin-off, Antares Therapeutics. He brings deep expertise in capital formation, disciplined capital allocation, and a track record of driving financial and operational excellence.

Why it matters

Sana Biotechnology is focused on developing engineered cell therapies, and Piper's leadership will be critical as the company continues to advance its portfolio, including generating initial clinical data for its type 1 diabetes and in vivo CAR T programs over the next 12-18 months.

The details

Piper was most recently CFO of Scorpion Therapeutics and its post-acquisition spin-off, Antares Therapeutics. Prior to that, he served as CFO of Prelude Therapeutics and Aevi Genomic Medicine. He also spent 13 years at Shire Pharmaceuticals in various finance roles.

  • Sana Biotechnology announced Piper's appointment on February 17, 2026.

The players

Sana Biotechnology, Inc.

A company focused on developing engineered cell therapies as medicines for patients.

Brian Piper

The newly appointed Executive Vice President and Chief Financial Officer of Sana Biotechnology, with over 25 years of biopharmaceutical financial and operational expertise.

Steve Harr

The President and Chief Executive Officer of Sana Biotechnology.

Got photos? Submit your photos here. ›

What they’re saying

“I am thrilled to welcome Brian to Sana and to our leadership team. He brings deep expertise in capital formation and disciplined capital allocation along with a proven track record of driving financial and operational excellence.”

— Steve Harr, President and Chief Executive Officer (biospace.com)

“I am delighted to join the Sana team at a pivotal time as we build on the demonstrated clinical potential of hypoimmune-modified pancreatic islet cells in type 1 diabetes and start clinical development for the in vivo CAR T platform. I look forward to working closely with the team to ensure a strong balance sheet, drive operational excellence, and apply disciplined capital allocation in support of our vision for patient impact and shareholder value.”

— Brian Piper, Executive Vice President, Chief Financial Officer (biospace.com)

What’s next

Over the next 12-18 months, Sana Biotechnology expects to generate initial clinical data for its SC451 program in the treatment of type 1 diabetes and its SG293 program in a B-cell related disease, which will create important value inflection points for the company.

The takeaway

Sana Biotechnology's appointment of an experienced CFO with a proven track record in the biopharmaceutical industry signals the company's commitment to advancing its engineered cell therapy pipeline and optimizing long-term value creation for shareholders as it approaches key clinical milestones.